No Causal Link Found for COVID-19, Guillain-Barr é Syndrome
MONDAY, Jan. 4, 2021 -- There seems to be no causal association between COVID-19 and Guillain-Barr é syndrome (GBS), according to a study published online Dec. 14 in Brain.
Noting that reports of GBS have emerged during the pandemic, Stephen Keddie,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 4, 2021 Category: Pharmaceuticals Source Type: news
CDC Issues COVID-19 Vaccine Guidance for Underlying Conditions CDC Issues COVID-19 Vaccine Guidance for Underlying Conditions
The guidance had specific information for people with HIV, weakened immune systems, and autoimmune conditions such as Guillain-Barre syndrome and Bell ' s palsy who are planning to get the vaccine.WebMD Health News (Source: Medscape Pulmonary Medicine Headlines)
Source: Medscape Pulmonary Medicine Headlines - December 28, 2020 Category: Respiratory Medicine Tags: Infectious Diseases News Source Type: news
No Link Seen Between COVID, Guillain-Barr é Syndrome
Guillain-Barré syndrome is a rare autoimmune condition that attacks the peripheral nervous system, typically causing numbness, weakness and pain. In severe cases, it can cause paralysis and is sometimes fatal. (Source: WebMD Health)
Source: WebMD Health - December 18, 2020 Category: Consumer Health News Source Type: news
No Link Seen Between COVID, Guillain-Barr é Syndrome
FRIDAY, Dec. 18, 2020 -- There ' s no evidence of a link between COVID-19 and a serious neurological condition called Guillain-Barr é syndrome, British researchers say.
Guillain-Barré syndrome is a rare autoimmune condition that attacks the... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 18, 2020 Category: General Medicine Source Type: news
No Link Seen Between COVID-19, Guillain-Barr é Syndrome
FRIDAY, Dec. 18, 2020 -- There ' s no evidence of a link between COVID-19 and a serious neurological condition called Guillain-Barré syndrome, British researchers say.
Guillain-Barré syndrome is a rare autoimmune condition that attacks... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 18, 2020 Category: General Medicine Source Type: news
No association between COVID-19 and Guillain-Barr é syndrome
(University College London) Neuroscientists at UCL have found no significant association between COVID-19 and the potentially paralysing and sometimes fatal neurological condition Guillain-Barr é syndrome. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 13, 2020 Category: International Medicine & Public Health Source Type: news
Scientists Report First Case of Recurring Guillain-Barre Tied to COVID
THURSDAY, Dec. 10, 2020 -- The first known case of COVID-19 triggering a recurrence of Guillain-Barré syndrome has been reported by researchers.
Guillain-Barré syndrome -- which can be sparked by viral and bacterial infections -- is a... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - December 10, 2020 Category: General Medicine Source Type: news
Fears coronavirus can trigger Guillain-Barre syndrome in sufferers
In April 2020, a man complaining of weakness in his face and limbs tested positive for COVID-19 and triggered Guillain-Barré Syndrome, a rare disorder that can lead to paralyzation. (Source: the Mail online | Health)
Source: the Mail online | Health - December 9, 2020 Category: Consumer Health News Source Type: news
Rutgers reports first instance of COVID-19 triggering recurrent Guillain-Barr é Syndrome
(Rutgers University) Researchers at Rutgers Robert Wood Johnson Medical School have reported the first instance of COVID-19 triggering a recurrence of Guillain-Barr é Syndrome - a rare disorder where the body's immune system attacks nerves and can lead to respiratory failure and death. (Source: EurekAlert! - Infectious and Emerging Diseases)
Source: EurekAlert! - Infectious and Emerging Diseases - December 8, 2020 Category: Infectious Diseases Source Type: news
When Symptoms of Covid-19 Don ’t Go Away
Research is underway to assess the pandemic ’s long-term effects and find ways to prevent and treat lasting symptoms. (Source: NYT Health)
Source: NYT Health - October 12, 2020 Category: Consumer Health News Authors: Jane E. Brody Tags: Coronavirus (2019-nCoV) SARS (Severe Acute Respiratory Syndrome) Lungs Heart Post-Traumatic Stress Disorder Guillain-Barre Syndrome Source Type: news
SIMPONI ARIA ® (golimumab) Approved by the U.S. Food and Drug Administration for Active Polyarticular Juvenile Idiopathic Arthritis and Extension of Its Active Psoriatic Arthritis Indication in Patients 2 Years of Age and Older
HORSHAM, PA, September 30, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that the U.S. Food and Drug Administration (FDA) has approved SIMPONI ARIA® (golimumab) for patients 2 years of age and older for the treatment of active pJIA and has extended the PsA indication for this same patient population. “This latest FDA approval of SIMPONI ARIA for pediatric use in active pJIA and active PsA not only brings a new option to young patients living with these diseases but also adds to the growing body of evidence for this treatment,” said Mathai Mammen, M.D., Ph.D., Global Head, Jans...
Source: Johnson and Johnson - September 30, 2020 Category: Pharmaceuticals Source Type: news
Coronavirus-infected man, 57, is left paralysed after the disease triggers a rare condition
The Briton was rushed to A&E on April 13 after struggling to stand upright or move his arms, where a swab confirmed he was infected with Covid-19. He was diagnosed with Guillain-Barré syndrome. (Source: the Mail online | Health)
Source: the Mail online | Health - July 17, 2020 Category: Consumer Health News Source Type: news
Stanford biotech spinout snares $100M round on path toward IPO
Annexon Inc., a Stanford University spinout targeting a protein that could play a role in neurodegeneration and autoimmune and eye diseases, closed a $100 million round that may signal interest in an IPO.
The South San Francisco company, led by President and CEO Ted Love, is looking to inhibit a pathway called complement. It has pushed two drugs into clinical trials and has raised more than $250 million.
One drug, called ANX-005, is a monoclonal antibody in a Phase I/II study against Guillain-Barr é… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - July 2, 2020 Category: Biotechnology Authors: Ron Leuty Source Type: news
COVID-19 Update: Guillain-Barr é , States Quarantining Visitors COVID-19 Update: Guillain-Barr é , States Quarantining Visitors
These are the coronavirus stories you need to know about today.Medscape Medical News (Source: Medscape Emergency Medicine Headlines)
Source: Medscape Emergency Medicine Headlines - June 24, 2020 Category: Emergency Medicine Tags: Infectious Diseases News Source Type: news
First Reported US Case of Guillain-Barr é Linked to COVID-19 First Reported US Case of Guillain-Barr é Linked to COVID-19
A 54-year-old man from Pittsburgh is believed to represent the first documented US case of Guillain-Barre syndrome occurring soon after SARS-CoV-2 infection.Medscape Medical News (Source: Medscape Neurology and Neurosurgery Headlines)
Source: Medscape Neurology and Neurosurgery Headlines - June 24, 2020 Category: Neurology Tags: Neurology & Neurosurgery News Source Type: news
